Recent enforcement actions across testing facilities reveal an aggressive regulatory stance on data integrity
Recent enforcement actions across testing facilities reveal an aggressive regulatory stance on data integrity
Varad Diwate
At the start of an August 2025 inspection of a Hyderabad testing laboratory, FDA investigators watched staff attempt to remove two garbage bags containing torn chromatographic results and method validation sheets. That facility was among a global cohort of five firms cited in FDA Warning Letters between late December 2025 and late March 2026 for pervasive data integrity breakdowns.
Under 21 CFR § 211.22, statutory responsibility for testing integrity and batch disposition sits squarely with the quality unit, while warning letters are addressed directly to executive management. The regulatory affairs (RA) head plays a critical steering role, translating inspection observations into comprehensive remediation commitments and liaising with the agency. But the RA head cannot substitute for the quality unit's operational authority over laboratory controls and audit trails.
The enforcement ladder is short:
Data integrity relies on data being Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA), as codified in FDA’s Data Integrity and CGMP Guidance. ALCOA+ incorporates four additional principles formalised by the UK MHRA: Complete, Consistent, Enduring, and Available. Both agencies maintain identical expectations regarding the evidentiary standard of GxP records.
The audit trail is the verification mechanism. The FDA defines an audit trail as a secure, computer-generated, time-stamped electronic record that allows for the independent reconstruction of the course of events relating to the creation, modification, or deletion of an electronic record. The MHRA specifies that it must capture who, what, when, and why, while strictly preventing user deactivation or unauthorised reconfiguration.
Title 21 CFR Part 11 establishes criteria under which the FDA considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records. It comprises three subparts:
Two specific clauses drive core inspection scrutiny:
Enforcement actions land heavily on the quality unit, with laboratory controls close behind. Across this enforcement cohort, citations consistently targeted failures in quality unit oversight alongside severe laboratory control violations. They reinforce that analytical contract testing facilities are held to rigorous CGMP release standards.
Audits consistently identify common behavioural lapses:
The FDA’s Data Integrity Guidance highlights that shared logins inherently destroy individual accountability. Also, any testing, including preliminary, trial, or out-of-specification (OOS) runs, must remain part of the permanent analytical record. The verbs dominating FDA citations—destroyed, backdated, altered, replaced—make one truth clear: data integrity fails because of culture and governance, not software limitations.
An audit trail provides contextual verification. The FDA treats audit trail reviews as the digital equivalent of inspecting manual cross-outs, corrections, and footnotes on paper records. Regulatory guidance mandates that personnel reviewing data packages examine the associated audit trails concurrently, with final verification certified by the quality unit prior to batch release.
For quality and compliance leadership, audit trail review must be an integrated, non-negotiable step in batch release protocols.
Timing reconciliation is equally critical:
Where statutory rules do not mandate a specific review frequency, manufacturers must establish and document risk-based intervals tailored to their analytical workflows.
FDA remediation requirements mandate three elements in response to data integrity findings: a comprehensive retrospective investigation into the scope and root cause, a scientifically sound risk assessment evaluating patient safety and product efficacy, and an executive-backed global Corrective and Preventive Action (CAPA) plan.
Prior to an inspection, quality assurance and regulatory leadership should audit five core control points:
Every compliance check resolves to a single principle: can an external auditor accurately reconstruct the entire lifecycle of an operation, in strict chronological sequence, from the electronic and physical record alone? While enterprise software provides the infrastructure, data integrity depends entirely on organisational discipline. Quality and regulatory leaders must ensure these governance standards are operationalised across the shop floor long before an inspection takes place.
Disclaimer: Content provided by TNF India is for informational purposes only. While we aim to provide accurate data and strategic insights, information is subject to rapid market and technological shifts. This content should not replace independent due diligence or professional consultation. TNF India bears no responsibility for any actions taken, or financial losses incurred, in reliance on this material.
What an owner should receive at handover, and what actually arrives.
